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Introduction  
There have been several prospective studies of the effectiveness of hearing instruments for 
adults with single sided deafness (SSD), a condition that has been associated with significant 
psychological and social burden 1,2,3. A recent meta-analysis examined the evidence for 
various hearing instruments including devices that re-route signals from the impaired to the 
non-impaired ear via air conduction (ACD) or bone conduction (BCD), and cochlear 
implantation (CI) 4. Comparable outcomes were available across studies on a limited set of 
measures: the Speech Spatial and Qualities of hearing scale (SSQ) 5, the Abbreviated Profile 
of Hearing Aid Benefit (APHAB) 6, and the Hearing In Noise Test (HINT) 7. 
 
The systematic review identified that there was a paucity of data for comparisons between 
certain hearing instruments (Figure 1). For example, three studies directly compared ACD to 
the Unaided condition8–10 and three studies directly compared BCD and ACD8–10, whereas 
comparable outcomes for BCD vs the unaided condition were available from eight studies8–
15. Few studies compared these interventions to CI. The meta-analysis (MA) of data extracted 
from those studies was therefore limited by the specific comparisons that had been reported 
in the published literature. Revised estimates of the relative effects of these different 
treatment alternatives could be obtained using network meta-analysis (NMA) to fully utilise 
all available evidence, both direct and indirect. 
 
To understand NMA in lay-terms the following analogy is useful. We have 3 hypothetical 
treatments: A, B and C. In this scenario there is a lot of data comparing A vs B and A vs C 
but little to none comparing B vs C 16. These data form a network from which inferences can 
be made on the basis of the indirect relationships formed by the data. In other words, NMA 
allows us to draw meaningful conclusions about the relationship between intervention B vs C 
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even though we do not have little if any direct evidence to rely upon. It is therefore a 
statistical meta-analytic technique that incorporates both direct and indirect evidence 17. 
 
We believe that NMA has a role to play in reducing research waste by utilising both indirect 
and direct evidence to provide best estimates of treatment effects based on all the available 
evidence. The application of this meta-analytical approach allows for research effort to be 
targeted where there is the greatest amount of treatment uncertainty; i.e. where there are few 
direct comparisons and the incorporation of indirect evidence has a notable impact on the 
estimated size of the treatment effect. Conducting clinical trials is costly, and poorly targeted 
studies risk wasting scarce research budgets, moreover, errors in design can lead to an 
inability to draw meaningful clinical conclusions. Chalmers and Glasziou18 have estimated 
that 85% of all research effort translates to no meaningful or reproducible output. This may 
be due to various reasons including the underreporting of studies with disappointing results, 
selective publication of results or inappropriate study design. A cross-sectional analysis has 
demonstrated that up to half of all National Institutes of Health funded trial results remain 
unpublished at 30 months after trial completion 19. Furthermore, Glasziou states that ‘studies 
of published trial reports showed that the poor description of interventions meant that 40-89% 
were non-replicable’ 20. This poor conversion from research activity to real clinical benefit to 
patients is of great concern to all those involved in and relying upon clinical research.  
 
Kitterick et al’s MA identified 30 papers of an original 778 that met the criteria to be 
included in their review 4. These were identified using PICOS (participants, intervention(s), 
comparators, outcomes, and study designs) framework 21 to set parameters that were of 
interest. These can be summarised as (P) Patients with average PTA of ≤30dB loss in the 
better ear and ≥70dB loss in the better ear, (I) hearing instruments used in SSD, (C) hearing 
instruments, placebo and no intervention, (O) speech perception in quiet and in noise, sound 
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localization, hearing- and health-related quality of life, complications and adverse events, (S) 
Controlled trials and prospective observational studies. The studies from which data were 
extracted are outlined in Table 1 and show the interventions assessed and the outcome 
measures used.  One of the main observations arising from the systematic review and MA 
was the lack of data on comparisons between certain interventions (i.e. BCD vs ACD) and a 
lack of controlled trials that had been designed prospectively to have sufficient statistical 
power to detect treatment effects. The authors suggested that the effect sizes from the MA 
could be used to inform the sample sizes of future studies 4. 
 NMA is an attractive prospect in this context as it allows one to use all the available 
evidence to obtained revised estimates of treatment effects. With better estimates of effect 
size come better knowledge of where the greatest uncertainty lies, and better estimates of the 
sample sizes required to detect such effects in the context of future prospective clinical trials. 
The current study subjected data from the previous meta-analysis to NMA to examine 
whether the incorporation of indirect evidence changed the size and direction of treatment 
effects. The resulting changes were also assessed to identify the outcomes and comparisons 
with the greatest level of uncertainty, and to determine whether the required sample sizes 
based on the revised effect sizes would be feasible to recruit in future clinical trials. 
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Materials and Methods 
The original meta-analysis synthesised data obtained using a variety of outcome measures 
that followed a prescribed methodology (and thus were likely to have been administered 
consistently) and were used across multiple studies 4. The Speech Spatial and Qualities of 
Hearing Scale (SSQ) measures hearing difficulties across several domains including speech 
perception, spatial awareness of sound and sound qualities. It is designed to measure hearing 
disability across a range of scenarios including those that are affected by binaural function 5. 
The Abbreviated Profile of Hearing Aid Benefit (APHAB) measures listening ability across 
four six-item subscales: aversion to sounds, background noise, ease of communication and 
reverberation 6. The Hearing In Noise Test (HINT) assesses the ability of participants to 
understand sentences with a degree of background noise either presented directly ahead (co-
incident with the speech, S0N0) or presented towards the impaired ear (S0Nie) or the non-
impaired ear (S0Nne) 7. The test can also be conducted in the absence of background noise 
(SIQ). 
 
A network meta-analysis of data obtained using these outcome measures was conducted in 
four steps. First, the raw data obtained using the measures described above and the number of 
patients for whom data were available were extracted from each study listed in Table 1 and 
organised into a spreadsheet using Microsoft Excel. Second, these data were loaded into the 
R statistical programming environment and effect sizes were calculated for each individual 
study. As all studies used before-after designs, effect sizes were computed by dividing the 
observed pre-post treatment change on each outcome measure by the standard deviation of 
that change 22 using the ‘metafor’ package 23. The resulting values expressed the size of each 
effect in units of standard deviations. Third, the effect sizes for each outcome measure were 
subjected to traditional random-effects meta-analyses separately for each treatment 
comparison (e.g. BCD vs unaided). The analyses determined the pooled treatment effect on 
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each outcome measure for each treatment comparison 23 and represent the meta-analysis 
approach used in the original systematic review 4. We refer to these pooled effects as the 
‘direct evidence’. 
 
Fourth, and finally, all effect sizes for each outcome measure were subjected to a network 
meta-analysis to determine pooled effects based on indirect evidence using the graph-
theoretical method described by Rücker 24 as implemented in the ‘netmeta’ package for the R 
statistical programming environment 25. A simple explanation for the general approach is that 
the analysis determines the indirect evidence for a particular treatment comparison of interest 
(i.e. A vs B) based on the difference between the direct evidence for other treatment 
comparisons that involve one of the treatments of interest (e.g. A vs C and B vs C). The 
general approach to determining the ‘indirect evidence’ can be expressed mathematically in 
the following form adapted from Cipriani et al.26: ABindirect = ACdirect − BCdirect. We refer to 
the treatment effects produced by the network meta-analyses as the ‘network evidence’ as 
they combine both direct and indirect evidence. 
 
For each treatment comparison, the direct and indirect evidence and the ‘network evidence’ 
(the result of synthesising both direct and indirect evidence) are reported in terms of the mean 
effects and their 95% confidence intervals 27. Given the complexity of the network-based 
approach to determining treatment estimates based on direct and indirect evidence, metrics 
and tests have been proposed to aid interpretation of the resulting estimates of treatment 
effect. We report the proportion of direct evidence that contributes to the network evidence 
and a statistical test to compare the direct and indirect evidence to assess whether the 
assumption of consistency was violated 28. The pooled effects resulting from the use of direct 
and indirect evidence were also compared by noting whether the direction of the effect had 
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changed and the whether the size of the effect had changed. Effect sizes were categorized as 
‘small’ (<0.20), ‘medium’ (0.21 to 0.80), or ‘large’ (>0.8) 29. 
 
A sample size calculation was conducted for treatment effects based on direct and network 
evidence using G*Power 30, a free to use cross-platform statistical tool that is available as a 
download for Windows and Macintosh operating systems from the Hienrich Heine 
University, Dusseldorf 31. The sample size calculation determined the number of participants 
required to detect a given effect size with 80% power (probability of a false-negative of 0.2) 
and an alpha of 5% (probability of a false-positive of 0.05). The calculations were based on 
the assumption that future trials would know the expected direction of the effect (beneficial 
or harmful) and would be powered to detect changes in mean outcome scores between 
intervention and a control/comparator groups. Therefore, the sample size estimates were 
based on a one-tailed independent-samples t-test with an allocation ratio of 1:1 to the two 
groups.  
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Results 
Tables 2 and 3 lists the estimates of effect size for comparisons between the unaided 
condition, ACD, BCD, and CI for the self-reported outcomes (APHAB, SSQ) and speech 
perception outcomes (HINT), respectively. Inconsistency between direct and indirect 
evidence was not identified for the self-reported outcomes but was identified for the S0N0 and 
S0NNE conditions of the HINT (Z and p values in Table 3). The size of the change resulting 
from the incorporation of indirect evidence varied from negligible (0.01 standard deviations, 
SD) to notable (0.38 SD). In one case the incorporation of indirect evidence altered the 
direction of the mean effect of ACD from being detrimental to listening ability to being 
beneficial (ACD vs Unaided; SSQ). However, in all cases the 95% confidence intervals of the 
effect sizes estimated from direct and network evidence overlapped, with the incorporation of 
indirect evidence widening confidence intervals around the treatment effects. 
 
Table 3 reports sample size calculations performed using effect sizes based on direct and 
network evidence for comparisons between ACD, BCD, and the unaided condition. The 
incorporation of indirect evidence reduced the required sample size to detect changes in SSQ 
scores when comparing CI to unaided reduced from 36 to 26. However, the inclusion of 
indirect evidence increased the sample size required to detect changes in SSQ scores when 
comparing CI to ACD (46 to 48) and CI to BCD (42 to 204). 
 
Discussion 
Network meta-analysis is a useful adjunct to standard meta-analytical techniques in cases 
where there are multiple treatment options for a condition and few studies that directly 
compare certain pairs of interventions. It is a technique that is yet to be widely adopted 
in the otological sciences; for example, at the time of publication the only example in the 
field indexed on PubMed is a protocol for a NMA in sudden sensorineural hearing loss 
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32. The application of NMA in the context of hearing instruments for adults with SSD 
resulted in some notable changes in terms of both the direction and size of treatment 
effects. For example, when using SSQ to measure listening abilities with ACD compared to 
the unaided condition, the incorporation of indirect evidence revised the mean treatment 
effect on listening ability from being a small detrimental effect to a medium beneficial effect. 
Such cases highlight areas where there is considerable uncertainty over treatment effects. 
 
Differences in treatment effects based on direct and network evidence could arise due to a 
variety of factors. There may be an imbalance in the quantity of direct and indirect evidence. 
For example, the effect size associated with the difference in SSQ scores for CI vs BCD 
decreased substantially from 0.79 to 0.35, a 56% reduction, once the indirect evidence was 
considered and the network evidence had the lowest proportion of direct evidence (67%) 
across all the comparisons examined in the current study. In that case, direct evidence was 
available from only one trial that reported a large positive treatment effect8 whereas two 
studies reported comparisons of BCD with unaided condition using that outcome 
measure. Differences in study methodology or population could have could also have 
resulted in varying effect sizes across these studies. For example, the study that 
compared BCD to CI provided bone-conduction devices on a softband/tension clamp 
whereas all of the studies comparing BCD with the unaided condition used osseo-
integrated implants. Osseo-integrated (percutaneous) implants are more effective at 
transducing high frequencies than transcutaneous devices such as softband-mounted 
devices33. These factors and other differences in study designs, such as how the 
treatments were delivered and the duration of follow up, could account for the significant 
inconsistency between direct and indirect evidence noted for some of the treatment 
comparisons. 
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The substantial reduction in the estimated size of treatment effect of CI vs BCD with and 
without indirect evidence increased the required sample size by a factor of 5 (42 to 204). 
A similar implication arose when comparing ACD to the unaided condition using the 
HINT sentence test in a frequently-used testing configuration for patients with SSD; i.e. 
speech from in front and noise towards non-impaired (good) ear (S0NNE). The sample 
size increased from 50 patients to 150 when indirect evidence was considered. For 
certain outcome measures, the numbers needed to power studies adequately became 
infeasible if one considered the indirect evidence (e.g. using APHAB to measure 
outcomes in ACD vs unaided) or conversely were reduced to potentially-feasible levels 
(e.g. using SSQ to measure outcomes in ACD vs unaided). These examples illustrate 
how NMA could prevent an underpowered trial being conducted or avoid unnecessary 
burden by over-recruitment, and in doing so prevent wastage of scarce research 
resources. 
 
When discussing sample size calculations for future clinical trials, a distinction must be 
made between an observed difference reported in a published study, such as those 
incorporated into the current meta-analyses, and a clinically-important difference. In 
areas where researchers are unsure of a treatment effect it is expedient to determine the 
minimal clinically important difference (MCID) in the primary outcome of interest 34 . The 
MCID can be defined as the minimum change in outcome that is deemed clinically-
significant. For example, an increase in the SSQ score of a few points may be statistically 
significant following an intervention but may or may not give a patient a clinically-important 
(perceptible) benefit. It is therefore relevant not only to consider what effect sizes may be the 
subject of uncertainty (as indicated by large changes in Tables 2 and 3) and whether it 
feasible to conduct a trial based on the required sample size (Table 4), but also whether the 
estimated sample size is likely to be meaningful to the clinician and patient alike. 
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Integral to the challenge of meta-analysis is the difficulty of comparing differing 
methodologies and outcome measures and synthesising this into a meaningful discourse 
about the benefits of interventions. Comparison between trials can be facilitated by the 
development of Core Outcome Sets (COS) that offer the prospect of a uniform way of 
measuring interventions in the context of clinical trials 35. They can also inform the choice of 
primary outcome for future trial design by identifying outcomes that are important to patients. 
By adopting a COS it will be possible to directly compare interventions trials. There is 
currently a COS in development for adults with SSD 36, 37. 
 
Limitations 
The prospect of being able to use all available data to provide new evidence of treatment 
effectiveness and therefore inform clinical trial design and clinical decision making is 
undoubtedly attractive. Whilst NMA is able to adjust for bias when used in conjunction 
with conventional direct comparison techniques38, as with any statistical procedure there 
are limitations to the NMA technique. To carry out NMA, as with traditional MA, 
assumptions have to made to allow the grouping and comparison of studies that include 
but are not limited to: (1) the study populations are likely to respond in comparable ways 
to the treatments under consideration; (2) the interventions are delivered in a similar 
way; and (3) the study designs are broadly similar – this is the concept of 
‘transivity’26,39.An example of this is that when we compare populations that have 
received a CI to those that have received ACD or BCD. There are likely to be subtle 
variations between these groups, including differences in the characteristics of those 
eligible for implantation and fit for a surgical procedure versus those unable, ineligible, 
or unwilling to receive a cochlear implant. In addition, data were only available from a 
small number of studies with small sample sizes, restricting the evidence upon which any 
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inferences can be made about treatment effects, whether based on direct or network 
evidence. 
 
Indirect evidence such as that provided by NMA is not afforded the same status as direct 
evidence found in head to head comparisons, in part due to the fact that the application 
of this technique is still an emerging field 26. Donegan et al’s review of reporting and 
methodological quality in indirect analyses drew attention to the fact that the ‘underlying 
assumptions are not routinely explored or reported when undertaking indirect 
comparisons.’40. Chou also cites the limitation of indirect comparisons when comparing 
‘complex and rapidly evolving interventions’41. However, there is a move towards 
placing additional weight on indirect analyses as since 2015 10% of Cochrane reviews 
have utilised NMA42 , with some calling for a re-evaluation of the evidential status 
accorded to NMA42. This technique is therefore illustrated here as an adjunct to 
conventional head to head comparisons that may be useful in situations where some 
treatment comparisons are under-represented in the published literature.  
 
Conclusion 
The application of network meta-analysis to extend existing analyses published 
alongside systematic reviews or to supplement the conduct of future reviews can aid the 
design of future trials of interventions for hearing-related interventions. The current 
results suggest that there is considerable uncertainty surrounding some published 
estimates of treatment effects associated with hearing instruments for adults with SSD. 
These results, together with further research to establish MCIDs and ongoing work to 
define a COS for SSD, will help ensure that future trials are targeted to reduce known 
uncertainty around treatment alternatives and make effective use of limited research 
resources.  
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Figure 1: A schematic representation of the network of comparisons reported in the 
published literature of hearing instruments for SSD. The size of the arrows are 
approximately proportional to the frequency with which the various comparisons have 
been reported, with the actual numbers alongside the arrows (ACD: Air-conduction 
device; ; BCD: Bone-conduction device; CI: Cochlear Implant). 
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Table 1: Characteristics of the studies and data used to conduct the network meta-analysis. 
Study 
Total study 
sample size Comparisons Follow-up duration Outcome measures extracted 
Extracted data 
sample size 
Arndt et al. 2011a,b 11 ACD vs Unaided 3 weeks SSQ 10 
  BCD vs Unaided 3 weeks SSQ 11 
  ACD vs BCD 3 weeks vs 3 weeks SSQ 11 
  CI vs Unaided 12 months SSQ 11 
  ACD vs CI 12 mo. vs 3 weeks SSQ 11 
  BCD vs CI 12 mo. vs 3 weeks SSQ 11 
Desmet et al. 2012 10 BCD vs Unaided 18 days APHAB 10 
Dumper et al. 2009 15 BCD vs Unaided Not reported HINT (SIQ, S0N0, S0NIE, S0NNE) 15 
Niparko et al 2003 10 ACD vs Unaided 1 month APHAB, HINT (SIQ, S0N0, S0NIE, S0NNE) 10 
  BCD vs Unaided 4 months APHAB, HINT (SIQ, S0N0, S0NIE, S0NNE) 10 
  ACD vs BCD 4 mo. vs 1 mo. APHAB, HINT (SIQ, S0N0, S0NIE, S0NNE) 10 
Pai et al. 2012 25 BCD vs Unaided At least 6 mo. SSQ 25 
Saliba et al. 2011 21 BCD vs Unaided 6 months HINT (S0N0, S0NIE, S0NNE) 21 
Vermeire et al. 2009 20 CI vs Unaided 12 months SSQ 9* 
Wazen et al. 2003 18 ACD vs Unaided 
4 months APHAB, HINT (SIQ, S0N0, S0NIE, S0NNE) 13 (APHAB) 
16 (HINT SIQ) 
11 (HINT SiN) 
  BCD vs Unaided 4 months APHAB, HINT (SIQ, S0N0, S0NIE, S0NNE) 13 (APHAB) 12 (HINT) 
  ACD vs BCD 4 mo. vs 4 mo. APHAB, HINT (SIQ, S0N0, S0NIE, S0NNE) 13 (APHAB) 12 (HINT) 
Yuen et al. 2009 13 BCD vs Unaided 3 months APHAB 13 
APHAB: Abbreviated Profile of Hearing Aid Benefit; SSQ: Speech Spatial and Qualities of hearing scale; HINT: Hearing In Noise Test; *10 of 
the 20 participants had single-sided deafness, of which pre- and post-CI data were available for 9. 
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Table 2: Effect sizes based on direct, indirect, and network evidence for the self-reported outcome measures. Positive effect sizes indicate a 
more favourable outcome with the first intervention in each comparison. Z and p values relate to a test comparing direct with indirect evidence. 
Comparison Direct evidence Indirect evidence Network evidence w Z p 
APHAB       
ACD vs BCD -0.63 [-1.08; -0.18] 0.00 [-0.84; 0.84] -0.49 [-0.89; 0.10] 0.78 1.30 0.193 
ACD vs Unaided 0.14 [-0.27; 0.55] -0.58 [-1.61; 0.45] 0.04 [-0.34; 0.42] 0.86 -1.27 0.205 
BCD vs Unaided 0.51 [0.26; 0.77] ¾ 0.53 [0.28; 0.79] >0.99 ¾ ¾ 
SSQ       
ACD vs BCD 0.00 [-1.66; 1.67] -2.92 [-7.21; 1.37] -0.38 [-1.93; 1.17] 0.87 1.25 0.213 
ACD vs CI -0.75 [-2.44; 0.95] -0.61 [-4.88; 3.66] -0.73 [-2.30; 0.85] 0.86 -0.06 0.953 
ACD vs Unaided -0.07 [-1.74; 1.61] 1.85 [-1.52; 5.22] 0.31 [-1.19; 1.81] 0.80 -1.00 0.318 
BCD vs CI -0.79 [-2.49; 0.91] 0.54 [-1.87; 2.94] -0.35 [-1.73; 1.04] 0.67 -0.88 0.379 
BCD vs Unaided 0.71 [-0.47; 1.89] 0.46 [-4.12; 5.04] 0.69 [-0.44; 1.83] 0.94 0.10 0.918 
CI vs Unaided 0.86 [-0.36; 2.08] 3.62 [-0.96; 8.20] 1.04 [-0.13; 2.22] 0.93 -1.14 0.253 
APHAB: Abbreviated Profile of Hearing Aid Benefit; SSQ: Speech Spatial and Qualities of hearing scale; w: Proportion of direct evidence. 
Effect size categories: ‘small’ (<0.20), ‘medium’ (0.21 to 0.80), ‘large’ (>0.8). 
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Table 3: Effect sizes based on direct, indirect, and network evidence for the speech perception outcome measures from the Hearing In Noise 
Test. Negative effect sizes indicate a more favourable outcome with the first intervention in each comparison. Z and p values relate to a test 
comparing direct with indirect evidence. 
Comparison Direct evidence Indirect evidence Network evidence w Z p 
SIQ       
ACD vs BCD 0.38 [-0.10; 0.87] 0.21 [ -0.97; 1.39] 0.36 [-0.09; 0.81] 0.86 0.27 0.790 
ACD vs Unaided 0.26 [-0.17; 0.69] 0.02 [ -1.52; 1.56] 0.24 [-0.17; 0.65] 0.93 0.29 0.773 
BCD vs Unaided -0.11 [-0.47; 0.24] -4.07 [-14.98; 6.85] -0.12 [-0.47; 0.24] >0.99 0.71 0.478 
S0N0       
ACD vs BCD 1.04 [ 0.40; 1.68] -0.70 [-1.96; 0.55] 0.68 [ 0.11; 1.25] 0.79 2.44 0.015 
ACD vs Unaided 0.11 [-0.45; 0.67] 1.90 [ 0.20; 3.60] 0.29 [-0.25; 0.82] 0.90 -1.96 0.049 
BCD vs Unaided -0.38 [-0.76; 0.00] -3.36 [-8.74; 2.02] -0.39 [-0.77; -0.01] >0.99 1.08 0.278 
S0NIE       
ACD vs BCD 0.36 [-0.07; 0.79] 0.16 [-1.13; 1.45] 0.34 [-0.07; 0.75] 0.90 0.29 0.771 
ACD vs Unaided 0.78 [ 0.29; 1.27] 0.99 [ 0.07; 1.91] 0.83 [ 0.40; 1.26] 0.78 -0.39 0.695 
BCD vs Unaided 0.50 [ 0.23; 0.78] ¾ 0.49 [ 0.21; 0.76] >0.99 ¾ ¾ 
S0NNE       
ACD vs BCD 0.33 [-0.25; 0.91] -1.39 [ -2.89; 0.12] 0.11 [-0.43; 0.65] 0.87 2.09 0.037 
ACD vs Unaided -0.72 [-1.34; -0.09] 0.89 [ -0.39; 2.16] -0.41 [-0.97; 0.15] 0.81 -2.21 0.027 
BCD vs Unaided -0.49 [-0.88; -0.09] -46.42 [-62.11; -30.73] -0.52 [-0.91; -0.12] >0.99 5.74 0.000 
 SIQ: Speech in quiet; S0Nx: Speech presented from the front and noise presented from the front (x=0), the side of the impaired ear (x=IE) or the 
normal-hearing ear (x=N). w: Proportion of direct evidence. Effect size categories: ‘small’ (<0.20), ‘medium’ (0.21 to 0.80), ‘large’ (>0.8). 
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Table 4: Sample size calculations based on direct and network evidence. 
Measure 
ACD vs Unaided  BCD vs Unaided  ACD vs BCD  CI vs Unaided  ACD vs CI  BCD  vs CI 
D N D 
 
D N D 
 
D N D 
 
D N D 
 
D N D 
 
D N D 
SSQ 5050 360 -4690  52 54 +2  ¾* 174 ¾*  36 26 -10  46 48 +2  42 204 +162 
APHAB 1264 15458 +14194  98 90 -8  64 106 +42  ¾ ¾ ¾  ¾ ¾ ¾  ¾ ¾ ¾ 
HINT                        
  SIQ 368 432 +64  2046 1720 -326  174 194 +20  ¾ ¾ ¾  ¾ ¾ ¾  ¾ ¾ ¾ 
  S0N0 2046 296 -1750  174 164 -10  26 56 +30  ¾ ¾ ¾  ¾ ¾ ¾  ¾ ¾ ¾ 
  S0NIE 44 38 -6  102 106 +4  194 216 +22  ¾ ¾ ¾  ¾ ¾ ¾  ¾ ¾ ¾ 
  S0NNE 50 150 +100  106 94 -12  230 2046 +1816  ¾ ¾ ¾  ¾ ¾ ¾  ¾ ¾ ¾ 
*Could not be calculated as direct effect size » 0.  
 
